Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Symtuza

Janssen & Research Partnership win prestigious BHBIA Best Business Impact award

We are delighted to announce that Janssen and Research Partnership have won the BOBI (Best of Business Intelligence) Award in the Best Business Impact category at the BHBIA annual conference in London for our collaborative market research...

Research Partnership

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to...

Research Partnership

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

- PMLiVE

ViiV’s two-drug HIV combo backed by CHMP

The committee also backs two biosimilar medicines

Research Partnership and Janssen are 2017-18 BOBI Awards finalists

We are delighted to announce that an entry submitted by Research Partnership with Janssen has been selected as a finalist in the Best Business Impact category at this year’s BOBI...

Research Partnership

- PMLiVE

Theratechnologies’ last-ditch HIV drug approved by FDA

The injectable becomes an add-on treatment for patients who have previously taken ART

Gilead Sciences

Gilead says switching studies back new HIV therapy Biktarvy

Patients who switched from rival Triumeq could maintain viral suppression over the trial period

Gilead Sciences

Gilead study resurrects HIV eradication hope

Intends to start human trials of its improved bNAb candidate

- PMLiVE

ViiV starts trial of HIV-preventing injections for women

Cabotegravir could provide a new way for women to protect themselves

EU flag

Janssen’s Tremfya cleared for European use

EC approves the medicine to treat adults with plaque psoriasis

- PMLiVE

EC expands Janssen’s prostate cancer drug reach

Zytiga plus predinson/prednisolone will now treat mHSPC patients

- PMLiVE

GSK’s ViiV gets US okay for two-drug HIV regimen

Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links